site stats

Irinotecan ic50

WebIrinotecan (CPT-11, (+)-Irinotecan) is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively. CAS No. 97682-44-5 Selleck's … WebIrinotecan was less active against VX2 vs. HepG2 (IC50=44.5 μM vs. 15.3 μM). Bevacizumab had no effect on either of the cell lines up to 6.7 μM. Conclusion: Drugs recommended for pre-clinical trials of TACE in the VX2 model are doxorubicin, sunitinib, sorafenib, MMC, lapatinib and 5-FU.

RNA-seq reveals determinants for irinotecan sensitivity/resistance …

Web(B) Calculation of 5-FU IC50 value by nonlinear regression in 2D and 3DTS. (D) Summary table of IC50 values obtained with PANC-1 and Aspc-1 cells following treatments with 5-FU and FOLFIRINOX ... WebApr 14, 2024 · IC 50 value of irinotecan was more than 50 μM for 24 hours, while for 48 hours and 72 hours exhibited IC 50 41.69 ± .025 μM and 9.46 ± .108 μM, respectively, against HT 29 (Figure 6 and Table 2). ... The response dose curve graph was plotted to obtain the IC50 value. The cell viability was calculated as follows kookmin bank co. ltd total assets https://mixner-dental-produkte.com

Drug: Irinotecan - Cancerrxgene - Genomics of Drug Sensitivity in …

WebApr 13, 2024 · diarrhea, constipation; nausea, vomiting, stomach pain; loss of appetite, weight loss; weakness; or. hair loss. This is not a complete list of side effects and others … WebIC50 values (μM) of IT-141 compared to free SN-38 and irinotecan in cancer cell lines. Data are presented as mean ± standard deviation. Source publication IT-141, a Polymer Micelle... WebMay 22, 2024 · Background We investigated the role of the ETS-1 transcription factor in Head and Neck Squamous Cell Carcinoma (HNSCC) in multiple cisplatin-resistant HNSCC cell lines. Methods We examined its molecular link with SRC and MEK/ERK pathways and determined the efficacy of either MEK/ERK inhibitor PD0325901 or SRC inhibitor Dasatinib … kookla creations

National Center for Biotechnology Information

Category:Effective drug combinations in breast, colon and pancreatic …

Tags:Irinotecan ic50

Irinotecan ic50

Irinotecan in the treatment of colorectal cancer: clinical overview

WebSep 21, 2016 · PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I–interactive … WebIrinotecan (CPT-11, (+)-Irinotecan) is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively. Camptothecin (NSC-100880, CPT, …

Irinotecan ic50

Did you know?

WebUS20240074866A1 US17/703,312 US202417703312A US2024074866A1 US 20240074866 A1 US20240074866 A1 US 20240074866A1 US 202417703312 A US202417703312 A US 202417703312A US 2024074866 A WebIrinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy.Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride …

WebIrinotecan (CPT-11), a prodrug for treating metastatic colorectal cancer, is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively … WebMay 31, 2024 · c The IC50 values of gimatecan and irinotecan for each cell lines were calculated. Data are presented as the mean ± SD of three replicate assays. Data are …

WebThe IC50 of irinotecan in HT29, NMG64/84, COLO-357, MIA PaCa-2 and PANC-1 cells at 30 min were 200, 160, 100, 400 and 150 microg/ml, respectively, in the HTCA. All isolated … WebIrinotecan (CPT-11, (+)-Irinotecan) hydrochloride is an inhibitor of Topoisomerase I (Topo I) that exhibits cytotoxicity in LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively. CAS No. 100286-90-6 Selleck's Irinotecan hydrochloride has been cited by 14 publications Adv Sci (Weinh),2024e2201539 Cancers (Basel),202414 (5)1230

WebIrinotecan is a prodrug, and hydrolysis of irinotecan by the carboxyesterase-2 enzyme in many normal tissues is responsible for activation of irinotecan to SN-38, a potent …

WebApr 15, 2014 · Determination of IC50 doses for 21 CRC cell lines. 21 CRC cell lines were treated with nine doses of irinotecan for 144 h, and then the cell viability was detected by … kookmin bank co. ltd. singapore branchWebThe SDF1/CXCR4 signaling has Irinotecan ic50 been recognized as a critical pathway for the homing and tissue retention of hematopoietic progenitor/stem Irinotecan ic50 cells in the … kookmin bank sustainability bond reportWebirinotecan Cell line Irinotecan IC50 (μM) SW620 1.53 LS180 3.11 COLO741 3.57 COLO205 7.23 LOVO 7.64 CX-1 8.69 GP2D 9.89 SW48 10.02 RKO 10.78 HCT116 14.84 HCT15 17.81 SW480 18.26 SW1116 27.22 DLD1 28.58 CACO-2 30.90 D2 36.60 SW837 46.42 GP5D 47.22 CO115 53.95 HT29 120 LS174T 150 Figure 1. Determination of IC50 doses for 21 CRC cell kookmin bank locationsWebJan 22, 2016 · Currently used Top1 targeting drugs, such as irinotecan, etirinotecan (NKTR-102), or topotecan are derivatives of camptothecin. However, non-camptothecin derived next generation Top1 inhibitors, such as indenoisoquinolines, are currently being tested in clinical trials [ 4, 5] with promising results ( http://clinicaltrials.gov/show/NCT01245192 ). kookmin best insurance coWebNational Center for Biotechnology Information kookmin bank commerce commission nzWebCompound Viability screens Drug sensitivity AUC (Sanger GDSC1) Drug sensitivity AUC (Sanger GDSC2) Drug sensitivity IC50 (Sanger GDSC1) Drug sensitivity IC50 (Sanger GDSC2) Drug sensitivity AUC (CTD^2) Drug sensitivity (PRISM Repurposing Primary Screen) Drug sensitivity AUC (PRISM Repurposing Secondary Screen) Drug sensitivity replicate-level … kookmin best insurance co. ltdWebDec 12, 2024 · IC50 for susceptible cells was 0.03 μg/mL, while it was 5.7 μg/mL for resistant cells (Fanciulli et al., 2000). ... Approximately 47-fold resistance to irinotecan developed in S1 colon-cancer cells upon pulsed exposure to the agent (0.5 μM) for 48 h with a 7-day interruption (Wu et al., 2024). After three to five cycles of drug treatment ... kookmin best insurance co. ltd. us branch